Informatics infrastructure for public-private collaborations in neglected disease research
Efforts to develop new medicines for diseases of the developing world (DDW) have been somewhat fragmented in the past and progress has been limited, despite considerable investment. Public-private partnership (PPP) is becoming an essential model for research in neglected disease areas. However, collaboration on this scale presents unique challenges, some of which can be well managed with the right informatics tools…
GlaxoSmithKline (GSK) has pioneered a model of true open partnership with academia through the Tres Cantos Open Lab Foundation, a ground-breaking PPP initiative set up at GSK’s dedicated DDW research facility at Tres Cantos in Madrid. Since its inception in 2011, the Tres Cantos Open Lab Foundation has managed more than 50 projects of drug discovery efforts against tuberculosis, malaria and kinetoplastid diseases (including trypanosomiasis, ie, African sleeping sickness and Chagas disease, and leishmaniasis). It is the world’s first open laboratory to investigate diseases of the developing world.
The rest of this article is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!